Status:
ACTIVE_NOT_RECRUITING
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Lead Sponsor:
Yonsei University
Collaborating Sponsors:
Chong Kun Dang Pharmaceutical Corp.
Health Insurance Review & Assessment Service
Conditions:
Acute Myocardial Infarction (AMI)
Type 2 Diabetes Mellitus (T2DM)
Eligibility:
All Genders
19+ years
Brief Summary
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabe...
Detailed Description
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated substantial cardiovascular benefits in patients with heart failure and chronic kidney disease, independent of glucose-lowering effec...
Eligibility Criteria
Inclusion
- Adults aged ≥19 years
- Hospitalization with a primary diagnosis of acute myocardial infarction between September 2014 and June 2021
- Diagnosis of type 2 diabetes mellitus (T2DM)
- Prescription of either an SGLT2 inhibitor or a DPP4 inhibitor after index AMI
Exclusion
- Diagnosis of type 1 diabetes mellitus
- Gestational diabetes mellitus
- End-stage renal disease (ESRD) or history of kidney transplantation
- No use of either SGLT2 inhibitor or DPP4 inhibitor after index AMI
- Short-term use of SGLT2 inhibitor or DPP4 inhibitor (less than 30 days)
- Concomitant use of SGLT2 inhibitor and DPP4 inhibitor
- Incomplete or missing data for key study variables
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2026
Estimated Enrollment :
200000 Patients enrolled
Trial Details
Trial ID
NCT07198191
Start Date
September 1 2014
End Date
August 30 2026
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongin Severance Hospital, Yonsei University Health System
Yongin, Gyeonggi-do, South Korea, 16995